Medtronic 2013 Annual Report Download - page 2

Download and view the complete annual report

Please find page 2 of the 2013 Medtronic annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 145

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145

U.S.
Coronary
Cardiac Rhythm
Disease
Management
Surgical Technologies
Neuromodulation
Spine
Asia Pacic
Central and Eastern Europe
Greater China
Latin America
Middle East and Africa
Western Europe
and Canada
Structural Heart
Endovascular
Impact of excluding special charges. See page 9 for reconciliation of non-GAAP nancial measures.
As reported
5-year CAGR** of 6.5% for diluted earnings per share, excluding special charges. See page 9 for reconciliation of
non-GAAP nancial measures.
5-year CAGR** of 16.3% for diluted earnings per share.
**Compound Annual Growth Rate
+53-week year
$4.00
3.50
3.00
2.50
2.00
1.50
1.00
0.50
0
Diluted Earnings
Per Share
(in dollars)
’09 ’10+’11 ‘12 ’13
0
$18
15
12
9
6
3
’09 ’10+’11 ‘12
5-year CAGR** 3.9%
’13
Net Sales
(dollars in billions)
Research and
Development Expense
(dollars in billions)
’09 ’10+’11 ‘12
5-year CAGR** 4.3%
’13
$1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
00
$2.5
2.0
1.5
1.0
.5
’09 ’10+’11 ‘12 ’13
Return to Shareholders
(dividends issued and shares repurchased,
dollars in billions)
Cardiac and
Vascular Group
Restorative
Therapies Group
Innovating for life.
Delivering Solutions. Advancing Healthcare.
Medtronic 2013 Annual Report
World Headquarters
Medtronic, Inc.
710 Medtronic Parkway
Minneapolis, MN 55432-5604
USA
Tel: +1.763.514.4000
Fax: +1.763.514.4879
www.medtronic.com
The following are registered and unregistered trademarks of Medtronic, Inc. and
its affiliated companies: AdaptivCRT, Advisa MRI, Aquamantys System, BRYAN
cervical disc, CD Horizon, CoreValve, Endurant, Enlite, EnRhythm, Evera ICD,
StealthStation navigation, IN.PACT Admiral, MiniMed, O-arm, PEAK PlasmaBlade,
Resolute, RestoreSensor, Solera, SureScan, Symplicity, Transcollation, Viva CRT-D.
UC201305939 EN © 2013 Medtronic, Inc. All Rights Reserved Printed in USA
Delivering Solutions.
Advancing Healthcare.
2013 ANNUAL REPORT
75732me_cover.indd 1 6/28/13 3:48 PM
2013 Highlights
Business Revenue Mix* Geographic Revenue Mix
19%
30%
11%
11% 9%
7% 9%
5%
Our diversified portfolio includes medical technologies that address
many of the world’s most pressing medical conditions.
*The data in this schedule has been intentionally rounded to the nearest whole percent, and therefore
South Asia
1%
1% 2%
2% 4%
11%
55%
24%
Sales in emerging markets grew from 10 percent of total sales
in FY2012 to 11 percent in FY2013.
does not sum to 100%.
38%
Revenue From New Products
In FY2013, 38 percent of revenue came
from products introduced in the past
three years.
Every3
seconds
A Person’s Life is Improved by a
Medtronic Product or Therapy
In FY2013, we helped improve the lives
of more than 9 million people around
the world.
36
Consecutive Years of Increasing
Our Cash Dividend
Medtronic is a member of the S&P 500
Dividend Aristocrats Index and raised its
cash dividend by 8% in June 2013.